Clinical laboratory · 2025
Durable Complete Response to Pembrolizumab in MSI-H Advanced Pancreatic Cancer.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Türker Ali, Buyuksimsek Mahmut, Türker Irem K, Türker Mehmet, Alisan Irfan
Аннотация
BACKGROUND: Pancreatic ductal adenocarcinoma remains a highly aggressive cancer with limited treatment options and poor prognosis. Pembrolizumab has shown potential in patients with micro satellite instability-high tumors. We report a rare case of complete remission of metastatic pancreatic cancer.
METHODS: A 58-year-old male with MSI-H advanced PDAC, who progressed during adjuvant and metastatic first-line treatment, was treated with pembrolizumab showed significant clinical improvement.
RESULTS: Pembrolizumab led to complete response. At the time of the report, the patient had durable response of 13 months.
CONCLUSIONS: This case demonstrates the promising role of pembrolizumab in MSI-H advanced pancreatic cancer.
METHODS: A 58-year-old male with MSI-H advanced PDAC, who progressed during adjuvant and metastatic first-line treatment, was treated with pembrolizumab showed significant clinical improvement.
RESULTS: Pembrolizumab led to complete response. At the time of the report, the patient had durable response of 13 months.
CONCLUSIONS: This case demonstrates the promising role of pembrolizumab in MSI-H advanced pancreatic cancer.